A recent study published at the American Society for Metabolic and Bariatric Surgery Annual Scientific Meeting in Washington has found that weight-loss surgery was five times more effective than weekly injections of popular GLP-1 receptor agonists. The research, which analyzed data from 51,085 patients, showed that those who underwent bariatric surgery lost an average of 58 pounds two years later, compared to 12 pounds for patients taking injectable semaglutide or tirzepatide. This translates to a total weight loss of 24% in the surgical group, versus just 4.7% in the GLP-1 medication group. The study suggests that nearly 70% of patients with GLP-1 prescriptions may discontinue treatment within one year, highlighting the need for improved strategies to achieve desired results, such as closer adherence or metabolic and bariatric surgery.
Source: https://www.foxnews.com/health/weight-loss-surgery-trumps-popular-ozempic-treatment-shocking-new-comparison